Evicenter
MarkdownMedical informationP&T meetings
Inaxaplin (VX-147)

APOL1-mediated kidney disease

Launch
Not announced
Last updated
162 sources

Section 5 of 6

Economic information and modeling report

5 evidence topics · 4 sources

Modeling overview

Summary: published economic evaluations, HTA status, and commercial forecasts

No published cost-effectiveness analysis, budget impact model, or health technology assessment of inaxaplin or of any other APOL1-targeted therapy was identified, and no ICER review was identified. A 2025 narrative review states that the cost-effectiveness of emerging APOL1-targeted therapies “remains uncertain”. The only APOL1-related economic analysis identified is a “crude cost analysis” of donor genotyping at one center, in which 1 of 26 potential African American living donors had a high-risk genotype. A GlobalData forecast published in 2024 projects U.S. inaxaplin revenue of $138 million in 2034. Guggenheim Securities analysts assigned a 65% probability of success in primary AMKD and 45% in the type 2 diabetes population; Vertex investor relations stated that AMPLITUDE could address about 150,000 people in the U.S. and Europe ; Fierce Biotech reported that an FDA label covering the two AMPLIFIED cohorts would add about 100,000.

Published cost-effectiveness analyses, budget impact models, and HTA reviews of inaxaplin

No evidence found.

Budget impact model

Approach and framework

No evidence found.

Perspective and time frame

No evidence found.

Epidemiology and eligible population inputs

No evidence found.

Cost assumptions

No evidence found.

Model outcomes

No evidence found.

Results

Base case

No evidence found.

Scenario analyses

No evidence found.

Budget impact model discussion

No evidence found.